Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.

Plain-language guide to PMID 10754779 (2000): clinical trial of Follicle Stimulating Hormone in 30 patients.

Key Facts

PMID: 10754779
Journal: Journal of assisted reproduction and genetics
Year: 2000
Study type: Clinical Trial
Authors: Balasch J et al. (8 authors)
DOI: 10.1023/a:1009493829086

What This Study Did, in Plain Language

What Was Tested

Researchers studied Follicle Stimulating Hormone in this clinical trial publication.

The main goal in the present study was to compare follicular development and estradiol levels after ovarian stimulation in pituitary suppressed normally ovulating women undergoing IVF, using highly purified urinary follicle stimulating hormone (FSH) (u-FSH-HP) and recombinant FSH (rec-FSH).

A secondary variable in their study was embryo implantation potential, which is closely related to appropriate follicular development and oocyte competence.

For the main purpose of this study, 30 IVF patients (group 1) were treated during IVF consecutive cycles, using the same stimulation protocol, with u-FSH-HP in the first treatment study cycle and rec-FSH in the second one.

Who Took Part

The study group was 30 patients.

PubMed indexes the participants as adults, women only.

As a control group (group 2) for implantation rates obtained in cycles treated with rec-FSH, 30 additional IVF patients were included who underwent a second IVF attempt again with u-FSH-HP.

What Was Measured

PubMed files the paper under topics including Embryo Implantation, Embryo Transfer, Estradiol, Fertility Agents, Female, Fertilization in Vitro, Follicle Stimulating Hormone and Leuprolide.

What This Means in Plain Language

This is a clinical trial of Follicle Stimulating Hormone in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Journal of assisted reproduction and genetics), a journal based in Netherlands.

More context: all human trials.

All human trials and studies

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.